C
CTKB
Cytek Biosciences, Inc.
4.010
+0.050+1.26%After Hours: 4.110 +0.100 +2.49%19:10 05/22 EDT
OPEN/PREV CLOSE3.960/3.960
TODAY RANGE3.940-4.060
VOL853.54K
MARKET CAP517.86M
52 WEEK RANGE2.370-6.18
AVG VOL (3M)797.39K
% TURNOVER0.66%
TURNOVER--
P/E (TTM)-6.9449
% RANGE2.90%
EPS(TTM)-0.5774
P/E(FORWARD)-11.4571
P/B1.581
BVPS2.537
DIVIDEND--
P/S2.558
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP474.62M
SHARES OUTSTANDING129.14M
NEXT EARNINGS08/04-08/10
FREE FLOAT118.36M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·05/13 15:35
Cytek Biosciences Is Maintained at Overweight by Stephens & Co.
Dow Jones·05/13 15:35
Cytek Biosciences Price Target Cut to $4.75/Share From $5.50 by Stephens & Co.
TipRanks·05/13 12:29
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Dow Jones·05/12 16:41
Cytek Biosciences Price Target Cut to $5.50/Share From $6.00 by Morgan Stanley
Dow Jones·05/12 16:41
Cytek Biosciences Is Maintained at Equal-Weight by Morgan Stanley
TipRanks·05/12 15:22
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
TipRanks·05/09 01:50
Cytek Biosciences Balances Growth Momentum With Cost Pressures
Simply Wall St·05/09 00:54
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives
Benzinga·05/08 21:06
12 Health Care Stocks Moving In Friday's After-Market Session
TipRanks·05/08 13:00
Piper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)
Seeking Alpha·05/08 02:02
Cytek reaffirms $205M-$212M 2026 revenue outlook as U.S. growth rebounds